SLXN Stock Price, Chart, Stats & News
Silexion Therapeutics Ltd. (SLXN) does not currently pay a dividend.
SLXN chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.03% |
ROA | -165.10% |
ROE | -387.82% |
D/E | 0.18x |
Interest coverage ratio | -1292.44x |
SLXN valuation
P/E | – |
P/S | – |
P/B | 1.47x |
P/CF | -0.35x |
P/FCF | -0.06x |
P/OCF | -0.35x |
PEG | 0.02x |
EV multiple | -0.52x |
About
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor.
Similar securities
Based on sector and market capitalization
